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ABSTRACT (258 words) if Cmax and AUC targets are removed = 250 words 18 
Objectives: To determine tobramycin pharmacokinetic/pharmacodynamic (PK/PD) 19 
breakpoints for weight (WT) and height (HT) based dosing regimens for patients with cystic 20 
fibrosis (CF).  21 
Methods: A simulated data set of 5000 patients based on 331 patients with CF was created 22 
using NONMEM. PK parameters were derived for each patient from a published population 23 
model using Monte Carlo simulation. The abilities of 10 and 12 mg/kg/day and 3 and 4 24 
mg/cm/day to achieve standard and extended Cmax (20-30 and 20-40 mg/L) and AUC0-24 (80-25 
120 and 80-150 mg.h/L) target ranges were evaluated. PK/PD limits for a Cmax/MIC ratio ≥10 26 
and AUC0-24/MIC ≥110 for a range of MIC values and cumulative fraction of response (CFR) 27 
for Pseudomonas aeruginosa were also determined.  28 
Results: Higher proportion of patients achieved standard Cmax and AUC0-24 targets with 3 29 
mg/cm/day (64% and 62%, respectively) than with 10 mg/kg/day (43% and 48%, 30 
respectively). AUC0-24 estimates >120 mg.h/L were more common with WT-based dosing. 31 
With higher doses and targets, 72% achieved target peaks with 4 mg/cm/day and 65% with 32 
12 mg/kg/day. The PK/PD limits for a Cmax/MIC ratio ≥10 was 2 mg/L for lower doses and 2.5 33 
mg/L for higher doses and for an AUC0-24/MIC ≥110 was 0.5 mg/L for all regimens. The CFR 34 
for all regimens was >90% for Cmax targets and 66% to 79% for AUC0-24 targets.  35 
Conclusions: Using a tobramycin dose of 3 mg/cm/day rather than 10 mg/kg/day achieved 36 
similar PK/PD outcomes but dose and AUC0-24 ranges were narrower and the incidence of 37 
high AUC0-24 values was lower. HT-based doses should therefore be considered for patients 38 
with CF. 39 
INTRODUCTION (3355 words) 40 
 Cystic fibrosis (CF) is an inherited autosomal recessive disorder characterised by frequent 41 
lung infections. This results in repeated courses of antibiotics, particularly tobramycin. 42 
Recommended doses of tobramycin range from 10 - 15 mg/kg/day1-3 and aim to achieve 43 
concentrations likely to be effective against Pseudomonas aeruginosa (P. aeruginosa), which 44 
accounts for 44.5% of infections in UK adults with CF.4 Optimising both Cmax/MIC and daily 45 
area under the curve to MIC (AUC0-24/MIC) ratios has been found to correlate with measures 46 
of clinical efficacy, including forced expiratory volume in one second (FEV1), and forced vital 47 
capacity (FVC).1,2 Although nephrotoxicity had traditionally been associated with high trough 48 
concentrations, AUC0-24 has been suggested as a better predictor of nephrotoxicity, 49 
particularly when once daily dosing regimens are used.5 50 
 51 
For patients with CF, current tobramycin monitoring approaches include measuring Cmax 52 
(target 20 - 30 mg/L, 30 min after a 30-min infusion)6 and trough concentrations (target ≤1 53 
mg/L).  “Troughs” are often measured 18 hours after the dose since concentrations are 54 
usually undetectable at 24 hours.7,8  In Australia and New Zealand, AUC0-24 is used to 55 
monitor once daily aminoglycoside therapy,8 with a recommended target range of 90 – 110 56 
mg.h/L.9 57 
 58 
Although total body weight,3 body surface area10  and lean body weight11,12  have been used 59 
to individualise aminoglycoside doses, a large population study13 found that weight (WT) 60 
had no influence on clearance whereas including height (HT) in the model led to a small 61 
reduction in between patient variability. These results suggested that aminoglycoside doses 62 
for patients with CF might be better calculated from HT rather than WT. 63 
The aims of the current study were to use Monte Carlo simulations to compare the ability of 64 
three WT and two HT scaled tobramycin dosage regimens to achieve target Cmax and AUC0-24 65 
ranges and to determine the PTA and cumulative fraction of response (CFR) against P. 66 
aeruginosa.  67 
 68 
METHODS 69 
Dosage regimens and targets 70 
A simulated data set of 5000 patients was created using NONMEM Version 7.1.14 The 71 
distributions of clinical characteristics in these simulated patients were based on observed 72 
values from 331 patients with CF whose data were analysed in a previous study.13  The 73 
patient characteristics from this data set are summarised in Supplementary Table 1. Data 74 
were restricted to the following ranges: weight 30 – 108 kg; height 139 – 194 cm; age 14 – 75 
88 years, serum creatinine 60 – 209 µmol/L; creatinine clearance 26 - 181 mL/min. These 76 
restrictions ensured that the clinical characteristics of the simulated patients were 77 
consistent with the original data set. Renal impairment (a creatinine clearance <50 ml/min) 78 
was present in 1% of the original data set and 4% of the simulated patient data. WT-based 79 
tobramycin doses were calculated for each patient as follows: 10 mg/kg/day to a maximum 80 
of 660 mg;6 10 mg/kg/day with no upper limit; and 12 mg/kg/day, based on the 81 
recommendation of VandenBussche et al.15 Two new dosage regimens based on HT, 3 82 
mg/cm/day and 4 mg/cm/day, were also tested. The lower dose was calculated from an 83 
AUC0-24 of 106 mg.h/L multiplied by the median clearance (CL) estimate from the population 84 
pharmacokinetic model and scaled by dividing by the median HT.13 A higher target AUC0-24 of 85 
120 mg.h/L was used to determine the higher dose. All doses were administered over 30 86 
min. Individual pharmacokinetic (PK) parameters were then simulated for each patient using 87 
NONMEM and a published population model13 and used to predict Cmax (30 min after the 88 
end of the infusion) and AUC0-24 estimates arising from these dosage regimens.  89 
 90 
Two target ranges for Cmax were defined: the standard range of 20-30 mg/L was based on 91 
the TOPIC study6; the extended range of 20–40 mg/L was based on Staubes et al.16 An initial 92 
target AUC0-24 of 106 mg.h/L was calculated from the 10 mg/kg/day dose and PK parameters 93 
reported in the TOPIC study. 17 The AUC0-24 target range was then derived by examining Cmax 94 
concentrations, CL and AUC0-24 (daily dose/CL) estimates from the 77 patients (135 courses) 95 
within a previous population13 who received once daily tobramycin. Since AUC0-24 estimates 96 
in patients who achieved Cmax values of 20-30 mg/L were typically ≥85 mg.h/L, the lower 97 
limit of the range was defined as 80 mg.h/L.  It was difficult to identify an upper AUC0-24 limit 98 
since only 3 trough concentrations were above 1 mg/L. However, as 89% of the AUC0-24 99 
values in patients whose predicted troughs were <1 mg/L were <120 mg.h/L, this was set as 100 
the standard upper limit. The target AUC0-24 was then modified to the midpoint of this range 101 
(100 mg.h/L) in line with the recommendations of Couthard et al.18 The extended AUC0-24 102 
range was 80 – 150 mg.h/L, an increase of 25%.  103 
 104 
Pharmacokinetic/Pharmacodynamic (PK/PD) analysis 105 
PK/PD analyses were conducted using all five dosage regimens. Targets were set at a 106 
Cmax/MIC ratio ≥10, as recommended by Kashuba et al19 and an AUC0-24/MIC ratio ≥110,20 107 
and were calculated for each simulated patient at MICs ranging from 0.5 to 8 mg/L. For each 108 
regimen, the highest MIC at which the regimen achieved a PTA ≥90% was defined as the 109 
PK/PD susceptibility limit. CFR was estimated using tobramycin MIC distributions against P. 110 
aeruginosa obtained from the EUCAST website.21 The fraction of patients who were 111 
expected to achieve the target PK/PD index was multiplied by the fraction of the organism 112 
distribution at a particular MIC. The CFR was then calculated as the sum of all fraction 113 
products at each MIC value.22  114 
 115 
RESULTS 116 
Pharmacokinetic data 117 
Table 1 summarises the distributions of doses, Cmax and AUC0-24 values arising from the five 118 
sets of WT and HT scaled doses. In all cases, the ranges were narrower when doses were 119 
scaled according to HT rather than WT. When the 10 mg/kg dose was unrestricted, 20% of 120 
the simulated patients received doses above 660 mg (range 661 to 1054 mg). Table 2 shows 121 
that restricting the 10 mg/kg dose had little effect on the distribution of Cmax, and slightly 122 
increased the percentage of AUC0-24 values within the target range, mainly by reducing the 123 
percentages >120 mg.h/L and >150 mg.h/L.  The 3 mg/cm/day dosage regimen achieved 124 
both a higher percentage of Cmax and AUC0-24 estimates within their standard target ranges 125 
(64% versus 43% and 62% versus 51%, respectively) and lower percentages of high values 126 
(31% versus 50% and 27% versus 39%, respectively) when compared to the restricted 10 127 
mg/kg/day regimen.   With the higher doses of 12 mg/kg/day and 4 mg/cm/day, although 128 
the percentage of Cmax values within the extended range was higher with the HT-based 129 
regimen (72% versus 65%), the AUC0-24 results were similar (63% versus 61% within and 36% 130 
versus 37% above the range). 131 
 132 
Figure 1 shows the dose, Cmax and AUC0-24 distributions for each simulated dosage regimen, 133 
stratified according to BMI.  The percentage of simulated patients in each BMI category was 134 
as follow; underweight 35%, normal weight 54%; overweight 10%, and obese 1%. With WT-135 
based dosage regimens, both Cmax and AUC0-24 increased with increasing BMI. Patients 136 
whose BMIs were <18.5 kg/m2 typically achieved predictions within Cmax and AUC0-24 target 137 
ranges while patients whose BMIs were 30 kg/m2 achieved values above the ranges. In 138 
contrast, HT-based dosage regimens produced a flat distribution across all BMI categories.    139 
Figure 2 shows the Cmax and AUC0-24 distributions for each simulated dosage regimen, 140 
stratified according to renal function. No difference was observed in achieving peak and 141 
AUC0-24 targets in HT vs WT based doses in patients with normal renal function and renal 142 
impairment. However, there was tendency for those with renal impairment to have lower 143 
peak concentrations and AUCs0-24 compared with normal renal function group in all WT 144 
based dosage regimens.  On the other hand, the peak concentrations and AUCs0-24 were 145 
higher for those with renal impairment compared with no impairment for the HT based 146 
doses. The difference was highest with AUCs0-24 values than for peak concentrations.  147 
PK/PD analysis 148 
Figure 3 shows the PTA results for each tobramycin dosage regimen against a range of MICs.  149 
For a Cmax/MIC ratio ≥10, the PK/PD susceptibility limit was 2 mg/L for doses of 10 150 
mg/kg/day and 3 mg/cm/day, and 2.5 mg/L for 12 mg/kg/day and 4 mg/cm/day. For an 151 
AUC0-24/MIC ratio ≥110, the limit for all dosage regimens was 0.5 mg/L.  152 
 153 
All dosage regimens were predicted to achieve a CFR >90% against P. aeruginosa for a 154 
Cmax/MIC ratio ≥10 (91 % for 10 mg/kg/day and 3 mg/cm/day and 92% for 12 mg/kg/day and 155 
4 mg/cm/day). For a target AUC0-24/MIC ratio ≥110, the results with 10 mg/kg/day and 3 156 
mg/cm/day were similar (70% and 66%, respectively), increasing to 78% with a dose of 12 157 
mg/kg/day and 79% with 4 mg/cm/day.  158 
 159 
DISCUSSION 160 
This study used the clinical characteristics and population PK parameters of tobramycin 161 
derived from adult patients with CF to compare the abilities of a range of tobramycin 162 
dosage regimens to achieve Cmax, AUC0-24 and PK/PD targets. Doses based on HT achieved PK 163 
targets more consistently and with less variability than WT based dosage regimens but PTA 164 
and CFR results were similar. This might be explained by being height was less variable 165 
between patients and had a narrow range. In addition, tobramycin is a water soluble drug it 166 
distributes mainly into plasma and not to any great extent into fat.  167 
 168 
Target tobramycin Cmax values 30 min after a 30 min infusion for patients with CF are based 169 
on a Cmax/MIC ratio of 8-10, which results in a range of 20 – 30 mg/L for MICs of 2-3 mg/L, as 170 
used in the TOPIC study.6 As the EUCAST and BSAC breakpoint for Pseudomonas aeruginosa 171 
is 4 mg/L, Staubes and colleagues initially proposed a target of 30 to 50 mg/L for 172 
concentrations back-extrapolated to the end of a 1 h infusion.16 However, they revised this 173 
range to 20-40 mg/L after finding that 91% of local isolates of P. aeruginosa had an MIC 3 174 
mg/L. Differences in the duration of infusion, which can range from 5 mins to 1 hour, and in 175 
the definition of Cmax, make it difficult to compare studies directly.16,23,24 Nevertheless, the 176 
current study was consistent with the findings of Staubes et al16 as both found that >70% of 177 
Cmax values would be within 20-40 mg/L with a dose of 10 mg/kg/day. A target Cmax of up to 178 
35 mg/L was suggested by VandenBussche et al,15 who recommended a tobramycin dose of 179 
12 mg/kg/day, while a dose of 11 mg/kg/day was identified as optimal by Hennig et al.11 To 180 
cover these varying recommendations, the present study examined both standard and 181 
extended target ranges and two sets of dosage guidelines. The results demonstrated that a 182 
HT based dose of 3 mg/cm/day achieved the target Cmax for both the standard and extended 183 
ranges more consistently than WT based doses, which were more likely to achieve high 184 
concentrations. There was no advantage in increasing the dose to 4 mg/cm/day as the 185 
results were similar to those obtained with 12 mg/kg/day. 186 
 187 
Target Cmax ranges generally focus on efficacy and there is little information on tobramycin 188 
concentration-toxicity relationships in patients with CF. Previous studies have claimed that 189 
doses up to 15 mg/kg/day and Cmax values up to 56 mg/L were well tolerated.16,24-26 190 
Bragonier et al24 reported no nephrotoxicity in 7 pediatric patients given 15 mg/kg/day for 191 
10 to 14 days, although one patient complained of transient dizziness. Master and 192 
colleagues reported a mean Cmax (1 h post dose) of 41 mg/L in 23 pediatric patients treated 193 
with 13 mg/kg/day over 15 mins for 10 days and found no evidence of nephrotoxicity or 194 
ototoxicity.25 Similar Cmax values at 1 h post infusion were found by Vic et al26 following 15 195 
mg/kg/day over 30 min for 14 days to 12 pediatric patients; they reported that all patients 196 
had a normal audiogram on day 14 and no evidence of nephrotoxicity. It is not clear 197 
whether these small, paediatric studies can be extrapolated to an adult population. Using 198 
RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease) criteria, Staubes et al16 found 199 
a 10% incidence of nephrotoxicity in 179 patient encounters; ototoxicity was not assessed. 200 
 201 
Although tobramycin monitoring guidelines currently recommend a pre-dose concentration 202 
<1 mg/L,6 24 hour troughs are typically below quantification limits.7, 8 Furthermore, there is 203 
evidence that this target is unable to detect patients at risk of underdosing or overdosing 204 
and that a target AUC0-24 of 100 mg.h/L provides a better indicator of dose requirements.18 205 
The target AUC0-24 chosen for the present study is consistent with this value and the 206 
Australia Antimicrobial Therapeutic Guideline,9 while the lower limit of 80 mg.h/L is similar 207 
to previously reported values from clinical and survey studies.25,27 As no specific data on 208 
toxicity were available, the upper limit of 120 mg.h/L was based on typical AUC0-24 values 209 
and previously reported ranges.25,27  Master et al reported a mean AUC0-24 of 104 ± 19 210 
mg.h/L with an average dose of 13 mg/kg/day, which was well tolerated and associated with 211 
around 10% improvement in lung function on day 10 of therapy compared with admission.25 212 
The predicted AUC0-24 for 10 mg/kg/day, based on the average PK values from the study by 213 
Staubes et al ,16 was 119 mg.h/L, which is consistent with the limit set in the current study.  214 
The extended range of up to 150 mg.h/L, represents a relatively conservative increase of 215 
25%. Although there is little evidence to support this value, it does not seem excessive; 216 
Murry et al reported a 7.5% nephrotoxicity rate with aminoglycoside AUC0-24 values of up to 217 
200 mg.h/L.28 218 
 219 
The present study found that a fixed dose of 10 mg/kg/day resulted in a wide range of dose 220 
amounts and AUC0-24 estimates.  In all cases, the incidence of AUC0-24 estimates below 80 221 
mg.h/L was low (1%-11%) and high AUC0-24 values were common. Restricting the maximum 222 
dose to 660 mg, as recommended in the TOPIC study,6 produced only a small reduction in 223 
the risk of excessive AUC0-24 values as most doses were <660 mg.  In contrast, 3 mg/cm/day 224 
produced a narrower range of doses, required no restrictions and only 27% of AUC0-24 values 225 
were >120 mg.h/L. With 12 mg/kg/day, 69% of AUC0-24 estimates were >120 mg.h/L and, as 226 
illustrated in Figure 1, several were above 300 mg.h/L. Such high exposure is likely to 227 
increase the risk of nephrotoxicity. Although 4 mg/cm/day did not achieve such high values, 228 
74% of estimates were >120 mg.h/L and 36% >150 mg.h/L. This suggests that 4 mg/cm/day 229 
is too high and that 3 mg/cm/day is preferred to meet these targets. 230 
 231 
Although 62% of the patients in the original data set13 had a normal BMI, 34% were 232 
underweight and 2 were obese. It was interesting to examine the impact of BMI on Cmax and 233 
AUC0-24 predictions as Staubes et al found that patients whose BMIs were 18.5 – 24.9 kg/m2 234 
achieved higher Cmax values than patients with BMIs <18.5 kg/m2.16 The present study was 235 
consistent with these findings as there was a clear link between increasing Cmax and 236 
increasing BMI. In contrast to the findings with WT scaled doses, no trend was observed 237 
with HT based doses, Cmax or AUC0-24 estimates across the different BMI categories. When 238 
stratified based on renal function, AUC0-24 were lower for those with renal impairment for all 239 
WT scaled doses, while AUC0-24 tended to be higher with HT scaled doses. This indicates that 240 
with using HT, the impact of renal function on tobramycin dosing requirement is much 241 
apparent than with WT scaled doses.  242 
 243 
As AUC0-24/MIC and Cmax/MIC ratios have been found to correlate with lung function in  244 
patients with CF1,2 both were used in the present study to assess the PTA and CFR.  The MIC 245 
breakpoints of 2 – 2.5 mg/L identified for the Cmax target are below the EUCAST and BSAC 246 
sensitivity breakpoints against P. aeruginosa of 4 mg/L20,29 but consistent with Sherwin et 247 
al,30 who reported that 10 mg/kg/day achieved a Cmax/MIC target >10 for most paediatric 248 
patients if the MIC was <2 mg/L.  249 
 250 
The results for the AUC0-24/MIC target of >110 identified an MIC limit of 0.5 mg/L for all 251 
dosage regimens. These results differ from those of Butterfield et al31 whose simulation 252 
study identified an MIC limit of 1 mg/L with a dose of 10 mg/kg/day.  However, their 253 
simulations were based on a sample size of only 9 patients, and their mean tobramycin CL 254 
(3.83 L/h) was lower than the value of 4.92 L/h in the original study of 331 patients.13 255 
Butterfield et al31 recommended increasing the dose to 15 to 20 mg/kg/day if MICs were 2 256 
to 4 mg/L despite achieving AUC0-24 values >200 mg.h/L. The authors assumed these values 257 
to be safe, as Drusano and Louie32 had reported that AUCs up to 600 mg.h/L are not 258 
associated with nephrotoxicity. However, these were both simulation studies and it is 259 
unlikely that such high exposures would be accepted as safe in routine clinical practice.   260 
 261 
Analysis of the CFR identified a success rate >90% for all regimens for a Cmax/MIC ratio ≥10 262 
using the EUCAST MIC distribution for P. aeruginosa. This was not surprising since 83% of 263 
isolates had an MIC <1 mg/L against tobramycin.20 At an AUC0-24/MIC ratio 110, the CFR 264 
ranged from 66-70% with the lower dosage regimens and increased to 78% and 79% with 12 265 
mg/kg/day and 4 mg/cm/day. These results are in agreement with Butterfield et al,31 who 266 
found that the probability of treatment success was >80% for a dose of 10 mg/kg/day and 267 
isolates with an MIC ≤1 mg/L.   268 
 269 
Overall, the present study suggests that if the MIC of P. aeruginosa is <2 mg/L, doses of 10 270 
mg/kg/day or 3 mg/cm/day are sufficient to achieve Cmax/MIC targets but higher doses (12 271 
mg/kg/day or 4 mg/cm/day) would be required for pathogens with MICs up to 2.5 mg/L. 272 
However, none of the dosage regimens achieved the target AUC0-24/MIC ratio for pathogens 273 
with an MIC >0.5 mg/L. The current study indicated that all tested doses will not achieve 274 
MIC target of 3 or 4 mg/L and higher doses are required. However, the increase in dose will 275 
result in excess exposure and would be on the price of toxicity. Further studies are needed 276 
to establish which PK/PD parameter and target gives the best prediction for efficacy to 277 
manage P. aeruginosa infections in patients with CF. In addition, clinical studies are urgently 278 
needed to assess the safety of high tobramycin AUC0-24.  279 
 280 
The study has some limitations. Lack of clinical outcome data in the original data set meant 281 
that it was not possible to link the simulation results directly with efficacy or to define safe 282 
upper limits for Cmax and AUC0-24. Consequently, the values used in the simulations reflected 283 
previous publications or typical exposures.  Although renal function was generally good in 284 
the original population and obesity was rare (1% of patients had a CrCL <50 mL/min and 285 
<1% were obese), AUC0-24 values >150 mg.h/L and high Cmax predictions typically occurred in 286 
patients whose simulated CL was low and/or who had BMIs above 30 kg/m2. It is clear that a 287 
lower dose or longer dosage interval would be required for patients with renal impairment. 288 
The value of using an adjusted body weight to determine dose has been reported 289 
elsewhere16,23 and might be more appropriate than using actual WT for obese patients. The 290 
TOPIC study6 addressed this issue to some extent by restricting the maximum dose to 660 291 
mg/day. However, this approach only limits the dose for patients weighing more than 66 kg, 292 
does not address the issue of small, overweight patients and may risk underdosing patients 293 
whose ideal weight is >66 kg. Furthermore, the present study showed that while the 294 
restriction reduced the risk of excessive concentrations, the overall results were similar to 295 
those with the unrestricted dose. Problems related to obesity did not arise with HT-scaled 296 
dosing.   297 
 298 
Conclusions  299 
This simulation study based on data from a large population of patients with CF has 300 
demonstrated that a HT-based dosage regimen of 3 mg/cm/day produced a narrower range 301 
of doses, Cmax and AUC0-24 estimates than WT-based dosage regimens, higher percentages of 302 
concentrations and exposures within target ranges and a lower incidence of excessive 303 
exposure.   All dosage regimens achieved Cmax/MIC ratios >10 for pathogens with an MIC 2 304 
mg/L but AUC0-24/MIC ratios >110 could only be achieved if the MIC was 0.5 mg/L. These 305 
results suggest that HT rather than WT-based dosing should be considered for patients with 306 
CF who are undergoing treatment with intravenous tobramycin. 307 
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Table 1 Median and range of daily doses, Cmax and AUC0-24 for a range of weight and height 407 
scaled tobramycin dosage regimens for patients with cystic fibrosis 408 
 
10 mg/kg/day 
(max 660 mg) 
10 
mg/kg/day 
12 
mg/kg/day 
3 
mg/cm/day 
4 
mg/cm/day 
Daily Dose 
(mg/day) 
550 
(300-660) 
550 
(300–1054) 
656 
(365-1296) 
498 
(418-581) 
664 
(556–776) 
Cmax (mg/L) 
30.0 
(9.7-79.3) 
30.0 
(9.7–79.3) 
35.6 
(9.6-98.3) 
27.2 
(11.8-52.1) 
36.2 
(14.5-68.7) 
AUC0-24 
(mg.h/L) 
112 
(45-260) 
114 
(45–291) 
137 
(54-410) 
104 
(48-227) 
139 
(60-303) 
 409 
 410 
Table 2 The percentages of simulated patients whose Cmax and AUC0-24 estimates were 411 
below, within and above target ranges with a range of weight and height scaled dosage 412 
regimens 413 
Dosage regimen 
10 mg/kg/day 
(max 660 mg) 
10 
mg/kg/day 
12 
mg/kg/day 
3 
mg/cm/day 
4 
mg/cm/day 
Cmax (mg/L) 
<20 7 7 1.5 5 0.2 
20 - 30 43 43 25 64 20.4 
>30 50 50 73 31 79.4 
30 - 40 37 37 40 29 52.0 
>40 13 13 33 2 27.4 
 
AUC0-24 (mg.h/L) 
< 80 10 9 2 11 1 
80 – 120 51 48 29 62 25 
>120 39 43 69 27 74 
120 - 150 27 27 32 22 38 
>150 12 16 37 5 36 
Key:AUC0-24-daily area under the curve414 
                                                                                                                                                                                      
 415 
Figure Legends 416 
Figure 1 The distribution of daily doses, predicted Cmax and AUC0-24 using a range of 417 
weight and height-based tobramycin dosage regimens 418 
Key: BMI = body mass index where 1 = <18.5, 2 = 18.5-24.99, 3 = 25-29.99, 4 = ≥30 kg/m2.  419 
The solid black lines represent the target Cmax and AUC0-24 ranges  420 
 421 
Figure 2 The distribution of predicted Cmax and AUC0-24 using a range of weight and 422 
height-based tobramycin dosage regimens 423 
Key: CrCL = creatinine clearance where 1 = < 50 mL/min, 0 = > 50 mL/min.  424 
The solid black lines represent the target Cmax and AUC0-24 ranges  425 
 426 
Figure 3  Percentage probability of achieving a target (a) Cmax/MIC ratio ≥10 and (b) 427 
AUC0-24/MIC ratios ≥110 with weight (10 and 12 mg/kg/day) and height (3 and 4 428 
mg/cm/day) scaled doses over a range of MIC values.   429 
Key: The black solid line and closed circle (           ) represents the 10 mg/kg/day dose (max 430 
660 mg/day); the solid black line and open circle (          ) represents the 12 mg/kg/day dose; 431 
the grey solid line and closed square (          ) represents the 3 mg/cm/day dose; the grey 432 
solid line and open square (             ) represents the 4 mg/cm/day dose.  433 
434 
                                                                                                                                                                                      
Figure 1 435 
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Figure 2 441 
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Figure 3   444 
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Supplementary Table 1 Median and ranges for original data set patients’ characteristics.  452 
 453 
Variable Median (ranges) 
Age (years) 24.6 (14 – 88.4) 
Weight (kg) 53 (30 – 108) 
Height (cm) 166 (139-194) 
Serum Creatinine (µmol/L) 70 (19 – 209) 
Creatinine Clearance (mL/min) 94 (26 – 181) 
 454 
